Monopar Therapeutics Schedule 13G passive stakes

Saturn V Capital Management LP and Xiaoying Tian have reported beneficial ownership of 313,384 shares, representing 4.7% of Monopar Therapeutics' common stock.

Adage Capital Management, L.P. and associated entities have disclosed a beneficial ownership of 4.76% in Monopar Therapeutics Inc., including shares issuable from warrants.

Saturn V Capital Management LP and Xiaoying Tian have reported beneficial ownership of 345,626 shares, representing 5.2% of Monopar Therapeutics Inc.'s common stock.

Adage Capital Management, L.P. has reported beneficial ownership of 6.23% of Monopar Therapeutics' common stock, including shares issuable upon warrant exercise.

AstraZeneca PLC and its subsidiary, Alexion Pharmaceuticals, Inc., reported a 7.8% beneficial ownership stake in Monopar Therapeutics Inc. common stock.

RA Capital Management and its affiliates reported a 9.9% beneficial ownership stake in Monopar Therapeutics Inc., primarily through common stock and pre-funded warrants.

Janus Henderson Group plc and its affiliates report a 19.5% beneficial ownership in Monopar Therapeutics Inc. common stock.

Janus Henderson Group plc and its affiliates have disclosed a significant beneficial ownership stake of 19.2% in Monopar Therapeutics Inc. common stock.

Janus Henderson Group plc and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have filed an amended Schedule 13G disclosing beneficial ownership of 18.6% of Monopar Therapeutics Inc.'s common stock.

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G/A, disclosing a 9.9% beneficial ownership stake in Monopar Therapeutics Inc. as of December 31, 2024.

Tang Capital Management and its affiliated entities have reported a 0% beneficial ownership in Monopar Therapeutics Inc., indicating a complete divestment of their previous stake.

Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, has disclosed a significant beneficial ownership of 9.86% in Monopar Therapeutics' common stock as of December 31, 2024.

Janus Henderson Group plc and its affiliate have filed an amended Schedule 13G, reporting a combined beneficial ownership of 1,046,899 shares, or 17.2%, of Monopar Therapeutics Inc.'s common stock as of December 31, 2024.